GSK Bepirovirsen Wins FDA Priority Review Breakthrough Status
LONDON, United Kingdom, April 28, 2026 GSK has announced that its investigational antisense oligonucleotide therapy bepirovirsen has been accepted...
GSK
Advertisement
GSK Reports Strong ADC Data in Ovarian Cancer Study
London, United Kingdom | April 13, 2026 GSK plc has announced positive clinical data from its Phase 1 BEHOLD-1...
GSK Secures China Approval for Exdensur in Nasal Polyps Treatment
LONDON, UK, April 8, 2026 GSK has announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab),...
Samsung Biologics Acquires GSK U.S. Manufacturing Site
INCHEON, South Korea & ROCKVILLE, Maryland, USA — March 31, 2026 Samsung Biologics has officially completed the acquisition of...
GSK Wins China Approval for Exdensur in Severe Asthma
LONDON, UK — March 30, 2026 In a major advancement in respiratory medicine and biologic drug innovation, GSK plc...
Advertisements
GSK Bepirovirsen Wins EMA Review for Hepatitis B Drug
London, UK | March 27, 2026 EMA Accepts First-in-Class Hepatitis B Therapy for Review GSK has announced that the...
GSK RSV Vaccine Arexvy Gains FDA Approval for Adults 18–49
LONDON, United Kingdom, March 13, 2026 Global biopharmaceutical company GSK has announced that the U.S. Food and Drug Administration...
RSV Vaccine Data Show Reduced Cardio-Respiratory Risks
Real-World Evidence Strengthens Adult Prevention Impact February 17, 2026 | London, United Kingdom GSK has released new real-world effectiveness...
European Commission Expands GSK’s RSV Vaccine Use to Adults 18+
London, United Kingdom, January 26, 2026 — GSK announced that the European Commission (EC) has approved an expanded indication...
GSK Acquires RAPT in $2.2B Bet on Food Allergy Therapy
London, United Kingdom, January 21, 2026 — GSK has announced a $2.2 billion acquisition of RAPT Therapeutics, securing global...
Advertisement
